Article

Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected

Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.

Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.

In August the National Institute for Health and Care Excellence (NICE) rejected the Swiss drugmaker's drug Kadcyla for an aggressive form of breast cancer. Roche had proposed a discount for that drug, which carries a full list price of more than 90,000 pounds for a course of treatment.

Friday's decision promises to further sour relations between NICE and the world's biggest maker of cancer drugs, which two months ago said NICE was "not fit for purpose".

Read the report on Reuters: http://reut.rs/1CIwReZ

Related Videos
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo